[go: up one dir, main page]

RU2009148286A - Жидкая фармацевтическая композиция ботулинического токсина - Google Patents

Жидкая фармацевтическая композиция ботулинического токсина Download PDF

Info

Publication number
RU2009148286A
RU2009148286A RU2009148286/15A RU2009148286A RU2009148286A RU 2009148286 A RU2009148286 A RU 2009148286A RU 2009148286/15 A RU2009148286/15 A RU 2009148286/15A RU 2009148286 A RU2009148286 A RU 2009148286A RU 2009148286 A RU2009148286 A RU 2009148286A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
composition according
botulinum toxin
concentration range
Prior art date
Application number
RU2009148286/15A
Other languages
English (en)
Other versions
RU2440825C2 (ru
Inventor
Хун Хо ДЗЮНГ (KR)
Хун Хо ДЗЮНГ
Ги Хуеок ЯНГ (KR)
Ги Хуеок ЯНГ
Хак Воо КИМ (KR)
Хак Воо КИМ
Хее Донг ВОО (KR)
Хее Донг ВОО
Чанг Хоон Рхее (KR)
Чанг Хоон Рхее
Original Assignee
Меди-Токс, Инк. (Kr)
Меди-Токс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Меди-Токс, Инк. (Kr), Меди-Токс, Инк. filed Critical Меди-Токс, Инк. (Kr)
Publication of RU2009148286A publication Critical patent/RU2009148286A/ru
Application granted granted Critical
Publication of RU2440825C2 publication Critical patent/RU2440825C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1. Жидкая фармацевтическая композиция, включающая ботулинический токсин, полисорбат 20 и метионин. ! 2. Жидкая фармацевтическая композиция по п.1, в которой метионин присутствует в количестве от 0,5 до 100 мкмоль на 100 единиц ботулинического токсина. ! 3. Жидкая фармацевтическая композиция по п.2, в которой метионин находится в диапазоне концентрации от 0,5 до 100 мМ. ! 4. Жидкая фармацевтическая композиция по п.3, в которой метионин находится в диапазоне концентрации от 25 до 75 мМ. ! 5. Жидкая фармацевтическая композиция по любому из пп.1-4, в которой полисорбат 20 присутствует в количестве от 0,01 до 50 мг на 100 единиц ботулинического токсина. ! 6. Жидкая фармацевтическая композиция по п.5, в которой полисорбат 20 находится в диапазоне концентрации от 0,01 до 50 мг/мл. ! 7. Жидкая фармацевтическая композиция по п.6, в которой полисорбат 20 находится в диапазоне концентрации от 0,1 до 2,5 мг/мл. ! 8. Жидкая фармацевтическая композиция по любому из пп.1-4, в которой ботулинический токсин выбран из группы, состоящей из серотипов ботулинического токсина А, В, С, D, Е, F и G. ! 9. Жидкая фармацевтическая композиция по п.8, в которой ботулинический токсин является некомплексной формой или находится в комплексе с белком. ! 10. Жидкая фармацевтическая композиция по любому из пп.1-4, которая имеет рН в диапазоне от 5,5 до 7,0. ! 11. Жидкая фармацевтическая композиция по любому из пп.1-4, дополнительно включающая изолейцин. ! 12. Жидкая фармацевтическая композиция по п.1 или 2, в которой ботулинический токсин находится в диапазоне концентрации от 50 до 5,000 единиц/мл.

Claims (12)

1. Жидкая фармацевтическая композиция, включающая ботулинический токсин, полисорбат 20 и метионин.
2. Жидкая фармацевтическая композиция по п.1, в которой метионин присутствует в количестве от 0,5 до 100 мкмоль на 100 единиц ботулинического токсина.
3. Жидкая фармацевтическая композиция по п.2, в которой метионин находится в диапазоне концентрации от 0,5 до 100 мМ.
4. Жидкая фармацевтическая композиция по п.3, в которой метионин находится в диапазоне концентрации от 25 до 75 мМ.
5. Жидкая фармацевтическая композиция по любому из пп.1-4, в которой полисорбат 20 присутствует в количестве от 0,01 до 50 мг на 100 единиц ботулинического токсина.
6. Жидкая фармацевтическая композиция по п.5, в которой полисорбат 20 находится в диапазоне концентрации от 0,01 до 50 мг/мл.
7. Жидкая фармацевтическая композиция по п.6, в которой полисорбат 20 находится в диапазоне концентрации от 0,1 до 2,5 мг/мл.
8. Жидкая фармацевтическая композиция по любому из пп.1-4, в которой ботулинический токсин выбран из группы, состоящей из серотипов ботулинического токсина А, В, С, D, Е, F и G.
9. Жидкая фармацевтическая композиция по п.8, в которой ботулинический токсин является некомплексной формой или находится в комплексе с белком.
10. Жидкая фармацевтическая композиция по любому из пп.1-4, которая имеет рН в диапазоне от 5,5 до 7,0.
11. Жидкая фармацевтическая композиция по любому из пп.1-4, дополнительно включающая изолейцин.
12. Жидкая фармацевтическая композиция по п.1 или 2, в которой ботулинический токсин находится в диапазоне концентрации от 50 до 5,000 единиц/мл.
RU2009148286/15A 2007-07-10 2008-05-28 Жидкая фармацевтическая композиция ботулинического токсина RU2440825C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070069363 2007-07-10
KR10-2007-0069363 2007-07-10

Publications (2)

Publication Number Publication Date
RU2009148286A true RU2009148286A (ru) 2011-06-27
RU2440825C2 RU2440825C2 (ru) 2012-01-27

Family

ID=40228747

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009148286/15A RU2440825C2 (ru) 2007-07-10 2008-05-28 Жидкая фармацевтическая композиция ботулинического токсина

Country Status (10)

Country Link
US (5) US8617568B2 (ru)
EP (1) EP2170400B1 (ru)
JP (1) JP5259710B2 (ru)
KR (1) KR101087017B1 (ru)
CN (1) CN101687046B (ru)
BR (1) BRPI0813948B8 (ru)
CA (1) CA2690773C (ru)
ES (1) ES2391798T3 (ru)
RU (1) RU2440825C2 (ru)
WO (1) WO2009008595A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
JP5259710B2 (ja) * 2007-07-10 2013-08-07 メディ‐トックス、インク． ボツリヌス毒素の安定性が改善された薬学的液状組成物
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
CA2814054A1 (en) * 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
ES2810098T3 (es) * 2011-03-31 2021-03-08 Medy Tox Inc Preparación liofilizada de toxina botulínica
EP2731590B1 (en) * 2011-07-13 2018-05-23 The Foundry, LLC Methods and apparatus for delivering a therapeutic agent to nasopharyngeal mucosa targets
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
AR103243A1 (es) 2014-12-23 2017-04-26 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulínica
RU2722290C2 (ru) 2015-02-03 2020-05-28 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
WO2017188618A1 (en) * 2016-04-26 2017-11-02 Korea Prime Pharm Co., Ltd. A novel composition comprising botulinum toxin
SI3679946T1 (sl) * 2016-05-27 2022-04-29 Ipsen Biopharma Limited Tekoča nevrotoksinska formulacija, stabilizirana s triptofanom ali tirozinom
WO2018038585A1 (ko) * 2016-08-26 2018-03-01 주식회사 에이비바이오 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
TW202247855A (zh) * 2016-09-13 2022-12-16 美商愛力根公司 非蛋白梭菌毒素組成物
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
EP3641746B1 (en) 2017-06-19 2024-11-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
CN107540732B (zh) * 2017-08-31 2020-07-14 青海省畜牧兽医科学院 一种d型肉毒毒素的仿生矿化加工方法及应用
WO2020111852A1 (ko) * 2018-11-30 2020-06-04 주식회사 휴온스글로벌 보툴리눔 독소의 안정화 액상 조성물
KR102259423B1 (ko) * 2018-11-30 2021-06-02 주식회사 휴온스바이오파마 보툴리눔 독소의 안정화 액상 조성물
US20230165946A1 (en) * 2020-04-08 2023-06-01 Medytox Inc. Botulinum toxin pre-filled injectable formulation that facilitates discharge rate control and is stable
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
CN116133686A (zh) 2020-07-23 2023-05-16 玫帝托克斯股份有限公司 癌症治疗剂
KR102414997B1 (ko) 2020-09-29 2022-06-29 주식회사 엘지생활건강 안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물
US20230365957A1 (en) 2020-10-07 2023-11-16 Pro-Tox Inc. Vacuum drying method for botulinum toxin
KR20230001254A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
KR20230001260A (ko) 2021-06-28 2023-01-04 (주)메디톡스 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법
KR20230071072A (ko) * 2021-11-15 2023-05-23 (주)메디톡스 보툴리눔 독소 조성물
CN116440281A (zh) * 2022-01-07 2023-07-18 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物
WO2024091050A1 (ko) * 2022-10-28 2024-05-02 주식회사 파마리서치바이오 보툴리눔 독소를 포함하는 안정한 액상 제제
KR20250003215A (ko) 2023-06-30 2025-01-07 주식회사 휴온스바이오파마 폴리솔베이트 20 및 세린을 포함하는 보툴리눔 독소의 안정화 액상 조성물

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US656730A (en) * 1899-08-25 1900-08-28 Farbenfabriken Of Elberfeld Company Blue chrysazin dye and process of making same.
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
WO2000051829A2 (en) 1999-03-01 2000-09-08 Rexam Industries Corp. Decorative sheet material with chlorinated polyolefin adhesive layer
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
NZ520201A (en) * 2000-02-08 2004-04-30 Allergan Inc Botulinum toxin pharmaceutical compositions comprising a polysaccharide
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
KR20030027077A (ko) 2000-09-01 2003-04-03 쥬가이 세이야쿠 가부시키가이샤 장기 안정화 용액 제제
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
JP2006502116A (ja) * 2002-07-12 2006-01-19 メダレックス， インク． タンパク質の酸化分解を防ぐ方法及び組成物
US6803046B2 (en) 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US20060002862A1 (en) * 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
WO2004087059A2 (en) * 2003-03-26 2004-10-14 The University Of Texas Covalent attachment of ligands to nucleophilic proteins guided by non-covalent binding
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
AU2005274822B2 (en) * 2004-07-26 2008-10-30 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
GB2416692A (en) * 2004-08-04 2006-02-08 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
US7399607B2 (en) * 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
CN1946738A (zh) * 2005-03-03 2007-04-11 阿勒根公司 用于纯化肉毒毒素的不含动物产物的系统和方法
DE102005019302A1 (de) * 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) * 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
CN101326275B (zh) * 2005-10-07 2013-06-05 阿拉巴马大学 多功能离子液体组合物
WO2007044809A2 (en) * 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
MX2008006750A (es) * 2005-12-01 2008-09-03 Univ Massachusetts Lowell Nanoemulsiones de botulinum.
US20070264355A1 (en) * 2005-12-14 2007-11-15 Binary, Llc Binary compositions and methods for sterilization
EP1998742A2 (en) * 2006-03-08 2008-12-10 Nuviance, INC. Transdermal drug delivery compositions and topical compositions for application on the skin
AU2007329579A1 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
JP2009008595A (ja) * 2007-06-29 2009-01-15 Kenwood Corp ナビゲーション装置、ナビゲーション方法、および、ナビゲーションプログラム
JP5259710B2 (ja) * 2007-07-10 2013-08-07 メディ‐トックス、インク． ボツリヌス毒素の安定性が改善された薬学的液状組成物
US8883146B2 (en) * 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
KR20090120222A (ko) * 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
US9155772B2 (en) * 2008-12-08 2015-10-13 Philip Morris Usa Inc. Soft, chewable and orally dissolvable and/or disintegrable products
KR101135449B1 (ko) * 2009-03-10 2012-04-13 한국과학기술연구원 헤파라나제 활성 측정용 이온 복합체 나노 입자 및 그 제조방법
KR101736775B1 (ko) * 2009-06-30 2017-05-18 (주)아모레퍼시픽 복분자 추출물을 함유하는 피부 주름 개선용 화장료 조성물
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
ES2810098T3 (es) * 2011-03-31 2021-03-08 Medy Tox Inc Preparación liofilizada de toxina botulínica
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
WO2014066916A2 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
AU2014329606B2 (en) * 2013-10-01 2020-02-06 Dana-Farber Cancer Institute, Inc. Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using Fndc5
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
EP3504226A1 (en) * 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
KR102463881B1 (ko) * 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법

Also Published As

Publication number Publication date
EP2170400A1 (en) 2010-04-07
JP5259710B2 (ja) 2013-08-07
BRPI0813948A2 (pt) 2016-06-28
EP2170400A4 (en) 2010-09-08
EP2170400B1 (en) 2012-07-25
CN101687046B (zh) 2012-12-26
US12274739B2 (en) 2025-04-15
RU2440825C2 (ru) 2012-01-27
CA2690773C (en) 2013-09-17
KR101087017B1 (ko) 2011-12-09
US8617568B2 (en) 2013-12-31
US20100291136A1 (en) 2010-11-18
CA2690773A1 (en) 2009-01-15
US20190298813A1 (en) 2019-10-03
US20160206710A1 (en) 2016-07-21
JP2010532784A (ja) 2010-10-14
KR20090005963A (ko) 2009-01-14
US20210379165A1 (en) 2021-12-09
ES2391798T3 (es) 2012-11-30
US20140161783A1 (en) 2014-06-12
US10293034B2 (en) 2019-05-21
BRPI0813948B1 (pt) 2019-08-06
WO2009008595A1 (en) 2009-01-15
US9220780B2 (en) 2015-12-29
BRPI0813948B8 (pt) 2021-05-25
CN101687046A (zh) 2010-03-31

Similar Documents

Publication Publication Date Title
RU2009148286A (ru) Жидкая фармацевтическая композиция ботулинического токсина
ECSP088962A (es) Nuevos herbicidas
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
UA96473C2 (ru) Жидкая стойкая композиция, которая содержит антитело imc-а12
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
JP2010522208A5 (ru)
DE602005026031D1 (de) Kristalline formen von (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
NZ609469A (en) Improved high concentration anti-tnfα antibody liquid formulations
EA201001223A1 (ru) Стабилизированные белковые композиции
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
EA201791850A1 (ru) Борсодержащие малые молекулы
EA201000584A1 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
UA102236C2 (ru) Производные эритропоэтин-миметического пептида и их фармацевтические соли, их получение и применение
NZ711567A (en) Antibody formulations
EA200501675A1 (ru) Фармацевтическая композиция, содержащая лактат, и ее применение
EA200801164A3 (ru) Ингибиторы протеина, активирующего 5-липоксигеназу (flap)
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
EA201001212A8 (ru) Лечение микробных инфекций
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
FR2949782B1 (fr) Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.